Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
Kleinerman
E S
ES
Department of Cell Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Jaffe
N
N
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001709:Biotechnology; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004285:Dogs; D004337:Drug Carriers; D006801:Humans; D007167:Immunotherapy; D008081:Liposomes; D009000:Monocytes / Q000276:immunology; D012516:Osteosarcoma / Q000556:secondary / Q000628:therapy*; D010714:Phosphatidylethanolamines / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D010714:Phosphatidylethanolamines; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine